Changing The Subject (Part 1): Stop Trying To “Win” The Drug Pricing Debate
This article was originally published in RPM Report
Executive Summary
When it comes to pricing, it is worth remembering that the interests of buyers and sellers can never be truly aligned. So rather than trying to “win” the drug pricing debate, the pharmaceutical industry may be better served by steering it into new areas. We plan to propose some big ideas that might work in that direction.
You may also be interested in...
Smart Segmentation: Success In The Payer-Dominated Pharma Marketplace
As physicians lose decision-making authority to payers, argues Roger Longman of Real Endpoints, drug companies need to segment markets more effectively: the patient populations prescribers are most likely to treat and that will spark the fewest access battles; and the specific payer lines-of-business least inclined to block new drugs' use.
Changing the Subject (Part 2): Turning Turing Around By Offering A “National Center Of Pharmaceutical Supply”
Rather than try to “win” the drug pricing debate, the biopharma sector may be better served by coming up with new ideas to change the subject. We outlined our case for taking this approach – and the model for ideas that serve that goal – here
. Now we offer the first proposal: a national center for off-patent pharmaceutical production.
Rx Import Legislation: One Step Forward, Two Steps Back – And Odd Dance Partners
The strange politics of prescription drug importation legislation in the US are on display again, this time in the context of the FDA user fee reauthorization bill. Including the topic in the bill is a ‘big deal’ – but probably makes imports less likely.